A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

NCT06120504 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated as part of strategic considerations

Conditions

Lymphoma, T-Cell, Cutaneous
Hodgkin Disease
Lymphoma, T-Cell, Peripheral
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin

Interventions

DRUG: PF-08046045

Sponsor

Seagen, a wholly owned subsidiary of Pfizer